NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE71099 Query DataSets for GSE71099
Status Public on Jul 21, 2015
Title Comparative analysis of gene expression profiles in prostate cancer cells after treatment by Dexamethasone or CpdA
Organism Homo sapiens
Experiment type Expression profiling by array
Summary The project is directed to the development of selective glucocorticoid receptor agonists for anticancer therapy. Glucocorticoids (GC) are widely used in treatment of many types of cancer due to its ability to induce apoptosis in malignant cells (in blood cancer therapy) and to prevent nausea and emesis (in the chemotherapy of solid tumors). However, severe dose-limiting side effects occur, including osteoporosis, muscle wasting, diabetes and other metabolic complications. Both beneficial and harmful effects of glucocorticoids are due to selective activation or repression of particular genes by glucocorticoid receptor (GR). GR regulates gene expression via transactivation that requires GR homodimer binding to gene promoters and transrepression mediated via negative interaction between GR and other transcription factors as well as binding with negative glucocorticoid response elements (nGRE) in genes. GR transactivation is linked to metabolic side effects, while GR transrepression underlies glucocorticoid therapeutic action. Novel selective GR agonist Compound A (CpdA) prevents GR dimerization and transactivation, specifically activates GR transrepression, and has fewer side effects compared to glucocorticoids. Here we compare the gene expression profiles in prostate cancer cells treated with glucocorticoid Dexamethasone (Dex) or CpdA
 
Overall design LNCaP prostrate cancer cells were treated with Dexamethasone (1 uM), Compound A (1 uM) or solvent (Ethanol) for 16 h. Then cells were pelleted and total RNA was isolated with RiboPure kit (Ambion) according to manufacturer's protocol. The RNA samples were treated with TURBOTM DNase (Ambion). Quality control was performed with Agilent Bioanalyser.
 
Contributor(s) Budunova I, Lesovaya E
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Jul 20, 2015
Last update date Jul 22, 2015
Contact name Ekaterina Lesovaya
E-mail(s) lesovenok@yandex.ru
Phone +79104714128
Organization name N.N. Blokhin Cancer Research Center
Department Chemical Carcinogenesis
Street address Kashirskoe shosse 24-15
City Moscow
ZIP/Postal code 115478
Country Russia
 
Platforms (1)
GPL6104 Illumina humanRef-8 v2.0 expression beadchip
Samples (16)
GSM1823672 Control_1
GSM1823673 FA 8H_1
GSM1823674 CpdA 8H_1
Relations
BioProject PRJNA290359

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE71099_RAW.tar 3.4 Mb (http)(custom) TAR
GSE71099_supplementaryData.Rdata.gz 15.5 Mb (ftp)(http) RDATA
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap